CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 1,275 enrolled
Drug / intervention
F2C22C/DL001Z +18 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05823974
NCT05823974Phase 2Completed
CompareCT.gov

A Phase 1/2, Randomized, Dose-finding/Dose-confirmation Study to Evaluate the Reactogenicity, Safety and Immunogenicity of mRNA-based Multivalent Seasonal Influenza Vaccine Candidates Administered in Healthy Younger and Older Adults

GlaxoSmithKline·interventional·Posted Apr 21, 2023·Updated Jul 23, 2025

In Brief

A Phase 2 clinical trial evaluating F2C22C/DL001Z, F2B22A/DL001Z, and 17 other interventions for Influenza, Human. Completed, enrolled 1,275 participants across 41 sites in 4 countries.

Detailed Summary

The purpose of this study is to find and confirm the dose and asses the reactogenicity, safety and immune response of GlaxoSmithKline's (GSK) messenger RNA (mRNA)-based multivalent seasonal influenza vaccine (GSK4382276A) candidates administered in healthy younger and older adults (OA).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza, Human
CountriesBelgium, Canada, South Africa, United States
CollaboratorsCureVac

Timeline

Phase 2CompletedFinished
202420252026
First PostedApr 21, 2023
Enrollment StartApr 27, 2023
Primary CompletionJul 2, 2024
Study CompletionDec 18, 2024
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 3.2 years ago

Interventions

F2C22C/DL001Zbiological

Study intervention was administered intramuscularly in Phase 1, at Day 1.

F2B22A/DL001Zbiological

Study intervention was administered intramuscularly in Phase 1, at Day 1.

F2B22B/DL001Zbiological

Study intervention was administered intramuscularly in Phase 1, at Day 1.

F2B22C/DL001Zbiological

Study intervention was administered intramuscularly in Phase 1, at Day 1.

F2B22D/DL001Zbiological

Study intervention was administered intramuscularly in Phase 1, at Day 1.

F2B22E/DL001Zbiological

Study intervention was administered intramuscularly in Phase 1, at Day 1.

F2F22A/DL001Zbiological

Study intervention was administered intramuscularly in Phase 1, at Day 1.

F2F22B/DL001Zbiological

Study intervention was administered intramuscularly in Phase 1, at Day 1.

F2F22C/DL001Zbiological

Study intervention was administered intramuscularly in Phase 1, at Day 1.

F2F22D/DL001Zbiological

Study intervention was administered intramuscularly in Phase 1, at Day 1.

F2F22E/DL001Zbiological

Study intervention was administered intramuscularly in Phase 1, at Day 1.

Control 1combination

Control vaccine was administered intramuscularly in Phase 1, at Day 1.

F2F23D/DL001Z-NHbiological

Study intervention was administered intramuscularly in Phase 2, at Day 1.

F2F23A/DL001Z-NHbiological

Study intervention was administered intramuscularly in Phase 2, at Day 1.

F2F23B/DL001Z-NHbiological

Study intervention was administered intramuscularly in Phase 2, at Day 1.

Control 2combination

Control vaccine was administered intramuscularly in Phase 2, at Day 1.

F2F23C/DL001Z-NHbiological

Study intervention was administered intramuscularly in Phase 2, at Day 1.

Control 3combination

Control vaccine was administered intramuscularly in Phase 2, at Day 1.

F2F22F/DL001Zbiological

Study intervention was administered intramuscularly in Phase 1, at Day 1.